Document is current

Any future updates will be listed below

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

Crossref DOI link: https://doi.org/10.1007/s12325-018-0813-y

Published Online: 2018-10-16

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark